Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Mycocycle Inc. currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to 1 distinct examiner, KANE, TREVOR LOGAN, who is also the busiest examiner with 1 pending action. The prosecution is confined to 1 distinct art unit, reflecting a very focused and singular point of contact with the patent office.
Because there is only 1 pending office action, the immediate success of the company's patent strategy in this technology area depends entirely on the interaction with KANE, TREVOR LOGAN. The 1 distinct art unit involved will dictate the specific examination standards applied to the filing. This streamlined profile allows for a highly targeted response strategy. Practitioners should note that with only 1 examiner and 1 art unit, there is no internal baseline for comparing examiner behavior within this portfolio.
The 1 pending office action represents the entirety of the current active prosecution for Mycocycle Inc. in this sector. The lack of multiple art units or examiners simplifies the prosecution landscape. Practitioners can focus entirely on the 1 pending office action without needing to coordinate across different technical groups. This 1-to-1-to-1 relationship between the action, the examiner, and the art unit centralizes the strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KANE, TREVOR LOGAN | 1 | 68.8% | +53.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18524456 | MYCOREMEDIATION OF CONTAMINANTS | KANE, TREVOR LOGAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18524456 | MYCOREMEDIATION OF CONTAMINANTS | KANE, TREVOR LOGAN | — |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18524456 | MYCOREMEDIATION OF CONTAMINANTS | KANE, TREVOR LOGAN | 1657 | §103§112 | Non-Final OA | — | Pending | Nov 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMycocycle Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Trevor Logan Kane has the most, with 1 of Mycocycle Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
